APP Pharma acquires benztropine mesylate, levetiracetam & tranexamic acid injectables from Nexus Pharma - pharmabiz.com

APP Pharmaceuticals, LLC, a Fresenius Kabi Company, has acquired benztropine mesylate injection, levetiracetam injection and tranexamic acid injection from Nexus Pharmaceuticals, Inc. Under terms of the agreement APP takes complete ownership of these ...

APP Pharmaceuticals Acquires Three Products from Nexus - Marketwatch

Levetiracetam Injection (100 mg/ml, 5 mL) is therapeutically equivalent to the reference-listed drug Keppra(R). Tranexamic Acid Injection (100 mg/mL, 10 mL) is therapeutically equivalent to the reference-listed drug Cyklokapron(R). According to ...

APP expands portfolio of injectable critical care products - News-Medical.Net

Levetiracetam Injection and Tranexamic Acid Injection.     "The addition of these products broadens an already extensive portfolio of injectable APP critical care products," said John Ducker, president and chief executive officer of APP Pharmaceuticals.

Use of Anti-epilepsy Drugs in Newborns Questioned - Med India

The researchers found that the anti-epilepsy drug levetiracetam did not stunt synaptic growth. Animals treated with a third drug, lamotrigine, showed neural maturation, but it was delayed. An additional finding involved melatonin. When added to ...

UCB S.A. (UCB) - Financial and Strategic SWOT Analysis Review - new company profile report - Transworld News

The core products of the company includes Vimpat (lacosamide), Keppra (levetiracetam), Neupro (rotigotine), Nootropil (piracetam), Metadate CD (methylphenidate HCI), Cimzia (certolizumab pegol), Xyzal (levocetirizine), Zyrtec (cetirizine, including Zyrtec ...

Anti-epilepsy drug phenobarbital stunts neuronal growth - News-Medical.Net

The researchers found that the anti-epilepsy drug levetiracetam did not stunt synaptic growth. Animals treated with a third drug, lamotrigine, showed neural maturation, but it was delayed. An additional finding involved melatonin. When added to ...